Program
LY4057996
A development code. Also written as “LY4057996 SC” and “LY4057996 IV”.
Its studies are mostly in Diabetes Mellitus, Type 1, led by Eli Lilly.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Eli Lilly | 11 open or running | phase 1since Apr 18, 2025 | Apr 18, 2025 | Jul 2027phase 1 · NCT06945406 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Apr 18, 2025First study: phase 1 study in Diabetes Mellitus, Type 1First studyNCT06945406 · 124 planned · Germany
- Sep 29, 2026Primary completion moved from 2026-12 to 2027-03Date moved laterphase 1 · +3 months · NCT06945406
- Nov 17, 2026Primary completion moved from 2027-03 to 2027-07Date moved laterphase 1 · +4 months · NCT06945406
Ahead
- Jul 2027Primary completion: phase 1 study in Diabetes Mellitus, Type 1NCT06945406
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 1 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06945406Diabetes Mellitus, Type 1 · Germany | 1 | Recruiting | Jul 2027 | 124 |
How it is read
Names in the registry
- “LY4057996 SC”, 1 entry
- “LY4057996 IV”, 1 entry
Codes read as this program: LY4057996.
Conditions, from the studies’ own filings
- Diabetes Mellitus, Type 1, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.